University Hospitals Birmingham NHS Foundation Trust

Status Drug name NICE TAs Comments
Status: Amber Brivaracetam (Briviact®)

Initiation by a suitable specialist on the recommendation of a tertiary epilepsy specialist with ongoing shared care between primary care and a suitable specialist.For adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with severe refractory epilepsy warranting tertiary specialist input for patients who have tried three or more AEDs. The patient has used levetiracetam and has documentation of intolerance and patient is using a third line agent (perampanel, zonisamide, lacosamide, eslicarbazepine) which would be replaced by brivaracetam. ESCA required

Brivacetam ESCA

Status: Red Brodalumab (Kyntheum®)
Status: Red Brolucizumab (Beovu®)
Status: Red Bromocriptine tablets
Status: Amber Bromonidine eye drops

Specialist ophthalmologist recommendation

Status: Green Budenoside and Formoterol (Symbicort)

For asthma only. Non-formulary for COPD.

Status: Green Budenoside nebulised
Status: Amber Budesonide (Budenofalk® ) Suppositories

Specialist recommendation

Status: Red Budesonide 1mg orodispersible tablets (Jorveza®)
Status: Amber Budesonide 2mg rectal foam (2mg per 1 metered dose) (Budenofalk®)

Approved to support the shortage of Colifoam (June 2018)

Building healthier lives
Back to top